Rare tumours such as penile carcinoma have been largely neglected by the urology scientific community in favour of more common – and, therefore, more easily fundable – diseases. Nevertheless, penile cancer represents a rising burden for health-care systems around the world, because a lack of widespread expertise, ineffective centralization of care and absence of research funds have hampered our ability to improve the global care of these patients.